Pharmaceutical

BW-20507 by Argo Biopharma Australia for Hepatitis B: Likelihood of Approval

BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.

Oct 3, 2023 - 20:00
BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.
Read the original article

Tags:

Previous Article

BGBA-3055 by BeiGene for Solid Tumor: Likelihood of Approval

Next Article

CT-080 by First Condor Group for Esophageal Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Silence announces $120m private placement for depositary shares

Silence announces $120m private placement for depositar...

Feb 6, 2024

US Senate committee interrogates big pharma on “outrageously high” drug prices

US Senate committee interrogates big pharma on “outrage...

Feb 10, 2024

STAT+: Lawsuit raises antitrust and kickback allegations around cancer patient referrals

STAT+: Lawsuit raises antitrust and kickback allegation...

Sep 8, 2023